First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis
Predicting long-term prognosis and choosing the appropriate therapeutic approach in patients with Multiple Sclerosis (MS) at the time of diagnosis is crucial in view of a personalized medicine. We investigated the impact of early therapeutic response on the 5-year prognosis of patients with relapsin...
Saved in:
Similar Items
-
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study
by: David Levitz, et al.
Published: (2024-11-01) -
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data
by: Ashkan Pirmani, et al.
Published: (2025-07-01) -
Longitudinal Trajectories of Digital Cognitive Biomarkers for Multiple Sclerosis
by: Yi Chao Foong, et al.
Published: (2025-04-01) -
Temporal prediction and feedforward control in cerebellar ataxia during spontaneous, instructed, and adaptive auditory-motor coupling while walking
by: Lousin Moumdjian, et al.
Published: (2025-08-01) -
Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study
by: Tjalf Ziemssen, et al.
Published: (2025-02-01)